ESPERITE N.V. Trading Update. CryoSave stable, Genoma 45% growth
(Thomson Reuters ONE) -
Zutphen, The Netherlands - 3 November 2015
ESPERITE N.V. (Euronext: ESP, 'ESPERITE', or 'the Group') announces its trading
update for the quarter ended 30 September 2015. ESPERITE keeps growing at an
incremental pace and the prospects for Q4 remain positive. Consolidated revenue
increased in Q3 over the same period of last year by 5%. High-profile agreements
with some of the largest, most prestigious and influential health institutions
in Europe are starting to bear fruit. Increased visibility and strong brand
awareness has been attained throughout the targeted European markets.
Integration and increased synergies between divisions, notably Genoma with
InKaryo for predictive medicine, and CryoSave with The Cell Factory for stem
cells cryopreservation and regenerative medicine, continue to strengthen the
Group. The 2 to 3-month lag announced in the half year report for 2015 did not
widened during Q3 due to strong sales performance. This lag will likely be
carried out until Q1 2016. As a result, ESPERITE will end the year behind the
projected revenue. On the other hand, the high-growth potential of the new
markets is expected to have a positive effect on the results already in Q4.
GENOMA
Genoma continued its sharp growth over the reporting period with a 45% increase
compared to Q2. Expectations for Q4 and 2016 are high.
Existing markets
Genoma has achieved strong brand awareness and strengthen its position in Italy,
Spain, Serbia, Portugal, Hungary, Bulgaria and Greece. The agreement signed with
the John Paul II Foundation for Research and Molipharma, subsidiaries of
Catholic University of the Sacred Heart, will show results in Q4. In Spain,
Genoma has signed a first-of-its-kind agreement with a private insurance company
to introduce Genoma products to its clients. In Serbia, Genoma has become a
market leader in a short period of time.
New markets
The first two phases of the Group's geographical expansion strategy are now
completed. Operations in the new high-potential markets are already underway. In
France, first strategic agreements were negotiated during the reporting period
and will be signed in Q4. Operations and initial sales start to come from
Germany, Belgium, Austria and Turkey. In Switzerland, Genoma is fully authorized
and its non invasive prenatal test, Tranquility, is now accredited for
reimbursement under the Swiss mandatory health insurance system. Poland, Romania
and Ukraine are some of the new markets where Genoma is set to generate business
starting in Q4.
Continuous enhancement of products and pipeline
The fetal fraction calculation method for Tranquility and T52s was enhanced.
Serenity results start to pick up in various countries and the trend is expected
to replicate in other markets as well. Eventy, the colorectal cancer risk
screening test, is now fully validated.
Laboratory expansion
Genoma's state-of-the-art clinical genetic center in Geneva with Next Generation
Sequencing (NGS) technologies keeps increasing its throughput capacity,
achieving even greater efficiencies.
CRYOSAVE
CryoSave maintains new client intake. The revenue for Q3 was in line with the
revenue realised in Q2. Growth for the CryoSave revenue is expected for Q4.
Cross-selling strategies between CryoSave and Genoma products and services is
showing a positive trend. Also, our customers are now increasingly choosing to
cryopreserve cord tissue in addition to cord blood compared to the same period
of last year.
CryoSave laboratory in Geneva is fully operational and good progress in the
consolidation of activities further improved organisational excellence.
THE CELL FACTORY
The recently acquired patent on MSC-derived exosomes and ongoing R&D activities
will produce tangible results in the short term. The cost-effective production
of MSC and microvesicles will allow the Group to sell these to pharmaceutical
companies and hospitals for safer, more effective and affordable treatments of
all autoimmune, chronic and acute inflammatory diseases, including related
pharmaceutical compositions which target anti-inflammatory drugs to specific
tissues.
Frederic Amar, CEO of ESPERITE group: "Esperite continues steadily in its path
of growth and expansion. We are committed to excellency, to mastering the
technology and to establishing far-reaching alliances. We are confident in our
vision and strategy, results are backing us up".
About ESPERITE
ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading
international company in regenerative and predictive medicine established in
2000.
To learn more about ESPERITE Group, or to book an interview with CEO Frederic
Amar: +31 575 548 998 - ir(at)esperite.com or visit the websites at
www.esperite.com and www.genoma.com.
ESPERITE PR Q3 3.11.15:
http://hugin.info/143308/R/1963507/716461.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Esperite N.V. via GlobeNewswire
[HUG#1963507]
Unternehmensinformation / Kurzprofil:
Datum: 03.11.2015 - 07:18 Uhr
Sprache: Deutsch
News-ID 431315
Anzahl Zeichen: 6036
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ESPERITE N.V. Trading Update. CryoSave stable, Genoma 45% growth"
steht unter der journalistisch-redaktionellen Verantwortung von
Esperite N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
